by Rod Raynovich | Aug 1, 2011 | 2024-25 Life Science Portfolios, BIOgraph, Macro
Triggers: Debt Ceiling and Skilled Nursing Stocks There is a broad sell-off in healthcare stocks today on fears that the debt ceiling deal would cut healthcare spending.A few weeks ago a few hedgies were on CNBC touting their “short healthcare” trade so...
by Rod Raynovich | Jul 31, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Here is 2011 Deal Data from IVDnews.com one of the leading data and news sites covering Diagnostics. Contact IVD News for details on all IVD deals for 2011. Recent M&A examples from our focus diagnostic stocks are: Luminex (LMNX) acquisition of EraGen for $34M....
by Rod Raynovich | Jul 29, 2011 | 2024 Rayno Tools and Diagnostics Portfolio, 2024-25 Life Science Portfolios, BIOgraph
It was a tough week in Life Science Tools and Diagnostics with many crosscurrents: debt ceiling uncertainty, earnings shortfalls, lackluster economic data and European debt crisis. The usual positive buzz from the AACC offered little support. We will provide an...
by Rod Raynovich | Jul 28, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Rayno Life Science Portfolio Recovers Up 1.73%; Jobless Claims Help The thrashing of Illumina (ILMN) yesterday appears to be overdone as the stock is recovering to the $60 area on volume of over 3.5M shares as of mid-day trading.The Tools and Diagnostics sector is...
by Rod Raynovich | Jul 27, 2011 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
Dog Days of Summer Lie Ahead- Q3 Seasonality in Life Sciences is Weak A vicious 16% sell-off in Illumina Inc. (ILMN $58.43) due to revised 2011 guidance and subsequent analysts’ reduced outlook. Concerns about sales growth are a new concern. Revenue for Q2 was...
by Rod Raynovich | Jul 27, 2011 | BIOgraph, Macro
Weakness in tools such as ILMN ($59.30) down 15% is hurting biotech. Also our mid cap biopharma index is down 2.5% . So the NASDAQ-100 is favored due to the inclusion of AAPL, AMZN, INTC and MSFT etc and larger cap biotech stocks.
by Rod Raynovich | Jul 26, 2011 | BIOgraph
Last week we recommended that bulls trade the QQQ rather than pure biotech with ETF’s such as IBB. The strategy was based on the outperformance of biotech compared to tech given that the Q’s also have several large cap biotech stocks. Moreover with IBM and...
by Rod Raynovich | Jul 25, 2011 | BIOgraph
The Rayno Life Science Portfolio was down 1.76% today which in itself is not alarming but given the weekly volatility against a back-drop of macro issues it is time to avoid complacency. Let’s start with the MO players who are those investors with more money...
by Rod Raynovich | Jul 25, 2011 | BIOgraph, Macro
Note: we will return from vacation this week and focus on companies attending the AACC (American Association of Clinical Chemistry)Meeting in Atlanta this week). Market Down 0.5% as Both Parties Struggle to Come up with Debt Ceiling Plan One half hour into trading...
by Rod Raynovich | Jul 18, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Todays’ Movers : CSII and IMGN Life Science and Drug stocks hit their third day of selling about 4% off July highs but 6% higher than June lows. The bellwether ETF IBB remains 6% above intermediate support of 100.The healthcare sector overall was down 0.88%...
